Clinical Genomics Reimbursement Law In Russia.
1. Introduction
Clinical Genomics Reimbursement Law in Russia concerns the legal framework governing the financing, reimbursement and public coverage of genetic and genomic diagnostic services provided to patients for the prevention, diagnosis and treatment of diseases.
Clinical genomics involves the examination of an individual's genetic information to identify inherited disorders, genetic mutations, hereditary cancer risks, rare diseases and other medically significant conditions.
Examples include:
Whole Genome Sequencing (WGS).
Whole Exome Sequencing (WES).
BRCA1 and BRCA2 mutation testing.
Pharmacogenomic testing.
Genetic testing for rare diseases.
Molecular tumour profiling.
Prenatal genetic testing.
Next-generation sequencing (NGS).
Russia does not have one comprehensive statute that automatically guarantees reimbursement for every clinical genomic test. Instead, reimbursement operates through several interconnected legal mechanisms, including:
The constitutional right to healthcare.
Compulsory Medical Insurance (OMS).
Federal and territorial programmes of state healthcare guarantees.
Clinical recommendations and medical standards.
Specialised medical-care financing.
Judicial protection against unlawful denial of medically necessary healthcare.
The central legal question is whether a particular genetic test qualifies as medically necessary healthcare covered by the applicable state-guaranteed financing programme.
An important distinction must be made between medically indicated genetic testing and elective genetic testing undertaken for personal, ancestry or lifestyle purposes.
2. Constitutional foundation of genomic reimbursement
The Russian Constitution provides the foundation for public healthcare financing.
Article 41 of the Constitution of the Russian Federation establishes the right to healthcare and medical assistance.
It provides for free medical assistance in state and municipal healthcare institutions through the relevant budgetary and insurance financing arrangements.
This constitutional guarantee is important for clinical genomics because genetic testing may be an essential component of diagnosing and treating serious diseases.
For example:
A child with an unexplained neurological disorder may require genetic sequencing.
A cancer patient may require molecular testing to determine appropriate targeted therapy.
A patient with a suspected inherited metabolic disorder may require genetic confirmation before treatment.
Where a genomic investigation is medically necessary, the constitutional guarantee becomes relevant to determining whether the patient should bear the financial burden.
However, Article 41 does not mean that every commercially available genetic test must be provided free of charge.
The entitlement must be examined alongside the applicable healthcare legislation and state-guarantee programmes.
3. Federal Law No. 323-FZ: Fundamental healthcare legislation
The principal legislation is the Federal Law of 21 November 2011 No. 323-FZ, On the Fundamentals of Health Protection of Citizens in the Russian Federation.
Several provisions are particularly relevant.
Article 19 – Right to medical assistance
Article 19 recognises the right of individuals to medical assistance, including free assistance within the guaranteed state programme.
This provision provides an important legal basis for patients seeking access to medically necessary genetic investigations.
Article 37 – Organisation and provision of medical care
Article 37 requires medical care to be organised in accordance with applicable medical-care procedures, clinical recommendations and medical standards.
This is significant because genomic testing must be considered within the clinical management of the patient's condition.
For example, if a clinical recommendation identifies molecular-genetic testing as an appropriate diagnostic investigation, that recommendation may support the medical justification for requesting the test.
Article 80 – Programme of state guarantees
Article 80 concerns the programme of state guarantees for free medical assistance.
The programme determines the categories, conditions and financing arrangements under which healthcare services are made available without direct payment by eligible patients.
Legal significance: Law No. 323-FZ establishes the healthcare entitlement, while the relevant state-guarantee programme and insurance arrangements determine the practical scope of financing.
4. Federal Law No. 326-FZ: Compulsory Medical Insurance
The Federal Law of 29 November 2010 No. 326-FZ, On Compulsory Medical Insurance in the Russian Federation, provides the insurance-financing framework.
The Russian compulsory medical insurance system is commonly known as OMS.
It finances eligible healthcare services through federal and territorial insurance arrangements.
Clinical genomic testing may be financed through OMS when:
The investigation is medically indicated.
The relevant service falls within the applicable programme.
The healthcare organisation is authorised to provide the service.
The organisation has the necessary allocated medical-care volumes or financing arrangements.
The required referral and documentation procedures are followed.
A particularly important issue is the distinction between the availability of a test and the availability of insurance financing.
A hospital may possess sophisticated sequencing technology without necessarily having an allocated OMS-funded volume for every genomic investigation.
Similarly, the fact that a test is available at a private laboratory does not automatically establish that OMS must reimburse it.
Legal significance: Law No. 326-FZ provides the institutional and financial framework through which qualifying genomic investigations may receive public insurance funding.
5. Government Programme of State Guarantees: 2026–2028
A particularly important legal development is Government Resolution No. 2188 of 29 December 2025, approving the Programme of State Guarantees of Free Medical Assistance for 2026 and the planning period 2027–2028.
This is the relevant programme for the current 2026 legal framework.
It expressly addresses the financing of certain diagnostic investigations, including:
Molecular-genetic testing for cancer diagnosis.
Molecular-genetic investigations used to select anticancer drug therapy.
Non-invasive prenatal testing using cell-free fetal DNA in maternal blood.
Certain other specialised laboratory investigations.
The programme provides for separate financing arrangements for these investigations rather than treating them simply as ordinary outpatient services.
Законы РФ+1
Three important provisions deserve attention.
A. Separate financing of molecular-genetic investigations
The programme distinguishes molecular-genetic investigations from ordinary per-capita outpatient financing.
This is important because genomic investigations may involve specialised laboratory equipment, expensive reagents, bioinformatics and specialist interpretation.
B. Medical indication and referral
The programme provides that the treating physician delivering primary or specialised primary healthcare may prescribe the relevant diagnostic investigation where medical indications exist.
C. Licensing and institutional allocation
The allocation of diagnostic testing volumes between medical organisations depends on the relevant medical licence and the regional financing arrangements.
Therefore, a patient cannot assume that every licensed laboratory must perform every genomic test free of charge.
The practical entitlement depends on the test, medical indication, regional programme and available allocation.
Законы РФ+1
6. Which genomic tests can receive reimbursement?
The following examples illustrate how the reimbursement system operates.
| Genomic investigation | Potential reimbursement position |
|---|---|
| BRCA1/BRCA2 testing | May be covered for qualifying cancer patients |
| KRAS testing | May be covered for qualifying colorectal cancer patients |
| NRAS testing | May be covered for qualifying colorectal cancer patients |
| BRAF testing | May be covered for specified cancer diagnoses |
| EGFR testing | May be covered for qualifying lung cancer patients |
| MSI testing | May be covered for relevant cancer indications |
| WGS/WES for rare diseases | Depends on medical indication and applicable financing arrangements |
| Pharmacogenomic testing | Depends on clinical indication and programme coverage |
| Non-invasive prenatal testing | Expressly addressed in the 2026 programme |
| Preimplantation genetic testing | Subject to the applicable programme and referral arrangements |
An important practical example is provided by the National Medical Research Radiological Centre of the Russian Ministry of Health.
Its published patient information identifies several molecular-genetic investigations that may be covered by OMS, including BRCA1/BRCA2, KRAS, NRAS, BRAF, EGFR, c-KIT, PDGFRA and microsatellite instability testing.
The centre also explains that a physician's referral is required and that certain tests can be accessed through referral form 057/u-04.
ФГБУ «НМИЦ радиологии» Минздрава России
This list is an institutional illustration, not an exhaustive nationwide statutory list of all reimbursable genetic investigations.
7. Order No. 274n of 21 April 2022: Genetic healthcare organisation
Another important instrument is Ministry of Health Order No. 274n of 21 April 2022.
It establishes the procedure for providing medical assistance to patients with congenital and hereditary diseases.
The order regulates the organisation of healthcare for patients requiring genetic diagnosis, specialist consultations and appropriate medical supervision.
Its framework involves:
Medical genetic consultations.
Clinical and laboratory genetic investigations.
Diagnosis of hereditary conditions.
Coordination between healthcare institutions.
Specialist medical management.
Appropriate referral and laboratory arrangements.
The order applies to licensed healthcare organisations, including organisations in the state, municipal and private healthcare systems.
The important distinction is that the order regulates the organisation of genetic healthcare; it does not independently guarantee reimbursement for every genetic test.
Financing must still be assessed under the applicable state-guarantee and compulsory insurance programmes.
ГАРАНТ+1
8. Landmark Case Law: Supreme Court of Russia, 14 October 2019
Major judicial authority
Case: Supreme Court of the Russian Federation, Civil Division, Determination No. 51-КГ19-7, 14 October 2019.
This is particularly important for clinical genomics reimbursement because it directly concerns the recovery of expenses incurred for genetic testing.
Facts of the case
A child suffering from a serious neurological condition required genetic examination.
On 24 January 2017, a genetic specialist at the Medical Genetic Research Centre in Moscow recommended genetic investigation.
On 13 April 2017, a genetic specialist at the Altai Regional Diagnostic Centre also recommended genetic testing to investigate a possible hereditary disorder.
The family was informed that the test was not included in the applicable state-guarantee arrangements and would have to be paid for privately.
On 25 May 2017, the child's mother arranged genetic testing at a private laboratory.
The examination cost RUB 35,000.
The genetic results subsequently assisted the medical commission and doctors' consultation at the Russian Children's Clinical Hospital in determining appropriate treatment, which produced a positive effect on the child's health.
Legal dispute
The child's mother sought reimbursement from the regional health authorities.
The authorities refused, arguing that:
The genetic investigation was not included in the applicable medical standards.
It was not covered by the relevant state-guarantee programme.
The regional health authority lacked the necessary financial resources.
The dispute eventually reached the Supreme Court.
Supreme Court's reasoning
The Supreme Court examined the statutory right to medical assistance under Federal Law No. 323-FZ.
It considered the legal definitions of medical assistance, medical services and diagnosis.
The Court recognised the importance of the fact that the genetic investigation had been recommended by medical specialists for vital medical reasons and had contributed to determining the child's treatment.
The Court upheld the recovery of the RUB 35,000 expenditure for genetic testing.
Legal principle
The decision demonstrates that a patient cannot necessarily be denied protection merely because a medically necessary genetic investigation was not expressly included in the applicable medical standards or programme.
Where the investigation was medically necessary and formed part of the healthcare required for the patient's serious condition, the state-guaranteed right to medical assistance may justify reimbursement of expenses.
ГАРАНТ+1
Importance for clinical genomics law
This decision is especially relevant to:
Whole-exome sequencing for children with rare diseases.
Genetic investigations for unexplained neurological disorders.
Hereditary disease diagnosis.
Molecular-genetic testing required to determine treatment.
Disputes involving expensive genetic panels.
However, the judgment should not be interpreted as establishing automatic reimbursement for every privately purchased genetic test. Its importance lies in the judicial protection of medically necessary testing in the circumstances of the case.
9. Regional reimbursement and allocation disputes
Clinical genomics reimbursement in Russia is also affected by regional healthcare financing.
Under the compulsory medical insurance system, regional commissions play an important role in distributing medical-care volumes and financial resources among participating healthcare organisations.
A significant clarification appears in the Russian Ministry of Health letter of 28 October 2024, No. 15-1/И/1-21443.
The Ministry explained that the distribution and redistribution of outpatient medical-care volumes, including genetic-testing services, falls within the competence of the commission responsible for developing the territorial compulsory medical insurance programme.
This creates an important legal issue.
A patient may satisfy the medical requirements for genetic testing but encounter difficulties because the preferred medical organisation has not received the relevant funding allocation.
The distinction between medical necessity and institutional funding allocation is therefore central to reimbursement disputes.
Контур.Экстерн
10. Reimbursement procedure for patients
The usual procedure for accessing publicly financed clinical genomic testing involves the following stages.
Medical consultation
The patient consults a treating physician, oncologist, neurologist or medical geneticist.
Clinical justification
The physician establishes whether genetic testing is medically indicated.
Referral
The physician issues the appropriate referral and documents the diagnostic purpose.
Selection of an authorised laboratory
The patient is referred to an appropriately licensed medical organisation with the necessary financing arrangements.
Insurance verification
The medical organisation or insurance provider confirms whether the specific investigation is covered by OMS or another state-guarantee mechanism.
Genetic investigation
The laboratory performs the prescribed molecular or genomic examination.
Clinical interpretation
Genetic results are interpreted by appropriately qualified specialists and incorporated into the patient's treatment plan.
If a patient has already paid for medically necessary genetic testing, reimbursement may be pursued through an administrative complaint or legal proceedings, depending on the facts and applicable legal basis.
11. Legal grounds for refusing reimbursement
Not every refusal to finance genomic testing is unlawful.
Russian healthcare authorities and insurers may have legitimate grounds for refusing payment.
Common examples include:
1. Absence of medical indications
A genetic test undertaken purely for curiosity, ancestry investigation or general lifestyle information may not qualify for state-funded healthcare.
2. Lack of clinical justification
Where a test is not supported by the patient's clinical circumstances or relevant medical recommendations, reimbursement may be refused.
3. Non-participating laboratory
A private laboratory may lack the relevant insurance contract, licence or allocated medical-care volume.
4. Failure to follow referral procedures
A patient who independently purchases a commercial genetic test may face difficulties obtaining reimbursement.
5. Absence of applicable programme coverage
Some advanced genomic investigations may not have an established financing route under the relevant territorial programme.
Nevertheless, the Supreme Court's decision in Case No. 51-КГ19-7 demonstrates that the absence of express programme coverage should not automatically end the legal inquiry where testing was medically necessary.
12. Patient rights and legal remedies
Patients who believe that their genetic-testing reimbursement rights have been violated may pursue several remedies.
| Institution | Relevant function |
|---|---|
| Medical organisation | Review of the medical decision and referral |
| Insurance medical organisation | Examination of OMS coverage and quality-of-care complaints |
| Territorial OMS Fund | Supervision of regional insurance financing |
| Regional Ministry of Health | Review of regional healthcare obligations |
| Roszdravnadzor | Healthcare regulatory supervision |
| Prosecutor's Office | Examination of potential violations of statutory rights |
| Courts | Judicial protection and recovery of qualifying expenses |
A patient seeking reimbursement should preserve:
Medical referrals and geneticist recommendations.
Clinical records and medical commission decisions.
Laboratory invoices and payment receipts.
Genetic test results.
Correspondence refusing reimbursement.
Evidence showing how the test influenced diagnosis or treatment.
These documents can be important in establishing medical necessity and financial loss.
13. Important legal challenges in Russian clinical genomics reimbursement
A. Expensive whole-genome sequencing
Whole-genome sequencing can identify thousands of potentially relevant genetic variations.
However, its cost and complexity raise questions about whether the investigation is necessary for a particular patient and whether an appropriate public financing route exists.
B. Rare disease diagnosis
Patients with rare hereditary diseases may undergo multiple unsuccessful investigations before genomic sequencing provides a diagnosis.
The challenge is ensuring that the absence of a specifically listed investigation does not automatically deprive patients of medically necessary diagnostic assistance.
C. Precision oncology
Cancer treatment increasingly depends on molecular characteristics of individual tumours.
Russia's 2026 state-guarantee programme recognises the importance of molecular-genetic testing in selecting certain anticancer treatment regimens.
In particular, the programme requires relevant molecular-genetic and/or immunohistochemical investigation before specified anticancer treatment schemes can be financed.
Законы РФ
D. Regional inequality
Different regions may have different diagnostic capacities, financing allocations and access to specialised laboratories.
Consequently, access to genomic testing may vary depending on the patient's location and the organisation responsible for providing the service.
E. Scientific developments and reimbursement policy
Genomic medicine develops faster than traditional reimbursement systems.
New sequencing techniques, computational analysis and pharmacogenomic investigations create difficulties for regulators when deciding which technologies should receive public financing.
F. Genetic data and confidentiality
Genomic testing also generates sensitive personal information.
Federal Law No. 152-FZ of 27 July 2006, On Personal Data, and Federal Law No. 323-FZ provide relevant privacy and confidentiality protections.
Reimbursement arrangements should therefore be implemented alongside appropriate safeguards for the collection, processing, storage and disclosure of genetic information.
14. Important case-law analysis
The following judicial authority is particularly relevant to the subject.
| Case | Legal issue | Significance |
|---|---|---|
| Supreme Court, 14 October 2019, No. 51-КГ19-7 | Reimbursement of privately paid genetic testing | Recognises judicial protection for expenses incurred for medically necessary genetic investigation |
It is important to distinguish between directly relevant judgments and general healthcare precedents.
The 2019 Supreme Court determination is a directly relevant genetic-testing reimbursement decision. The legal analysis should not invent additional Russian Supreme Court precedents specifically concerning whole-genome sequencing reimbursement where such decisions have not been established.
15. Critical legal analysis
The Russian clinical genomics reimbursement framework demonstrates the interaction between three competing considerations.
First: Individual healthcare rights.
Patients with serious hereditary or acquired diseases require access to appropriate diagnostic technologies.
The constitutional right to medical assistance provides the foundation for protecting those interests.
Second: Financial sustainability.
Genomic testing can be expensive, and public healthcare resources are limited.
The OMS system therefore uses clinical indications, financing allocations, licensing requirements and programme-based payment mechanisms.
Third: Scientific and technological development.
Traditional medical reimbursement systems are often designed around established diagnostic procedures.
Modern genomics introduces more complex technologies, including whole-genome sequencing, polygenic analysis and personalised pharmacogenomics.
A legal system must therefore balance financial controls against the need to provide medically appropriate and scientifically justified diagnosis.
The Supreme Court's 2019 determination is important because it illustrates that administrative funding limitations do not necessarily resolve the underlying question of a patient's entitlement to medically necessary assistance.
16. Conclusion
Clinical Genomics Reimbursement Law in Russia is based on a combination of constitutional healthcare rights, Federal Law No. 323-FZ, Federal Law No. 326-FZ, Ministry of Health regulations and the annual Programme of State Guarantees.
The 2026–2028 programme under Government Resolution No. 2188 provides specific financing arrangements for molecular-genetic investigations, particularly in oncology, and addresses non-invasive prenatal testing and preimplantation genetic testing.
The Supreme Court's determination of 14 October 2019, No. 51-КГ19-7, remains a particularly important judicial authority because it confirms that medically necessary genetic examinations may receive judicial protection even where reimbursement has been administratively disputed.
Ultimately, the central principle is that clinical genomic reimbursement should be assessed according to medical necessity, statutory healthcare guarantees, applicable insurance coverage and the patient's individual circumstances—not merely the commercial price or technological complexity of the genetic test.
17. Important legal authorities and references
Constitution of the Russian Federation, Article 41.
Federal Law No. 323-FZ of 21 November 2011, On the Fundamentals of Health Protection of Citizens in the Russian Federation.
Federal Law No. 326-FZ of 29 November 2010, On Compulsory Medical Insurance in the Russian Federation.
Government Resolution No. 2188 of 29 December 2025, State Guarantees Programme for 2026–2028.
Ministry of Health Order No. 274n of 21 April 2022, concerning medical assistance for patients with congenital and hereditary diseases.
Federal Law No. 152-FZ of 27 July 2006, On Personal Data.
Supreme Court of the Russian Federation, Determination No. 51-КГ19-7, 14 October 2019.
Ministry of Health letter No. 15-1/И/1-21443 of 28 October 2024, concerning the allocation of medical-care volumes, including genetic testing.
Useful primary and institutional sources
Russian Government Resolution No. 2188 – 2026–2028 healthcare guarantees.
National Medical Research Radiological Centre – Molecular Genetic Testing and OMS coverage.
Supreme Court determination No. 51-КГ19-7 (14 October 2019).
Ministry of Health Order No. 274n – hereditary disease healthcare.
Academic note: This analysis distinguishes between an express reimbursement entitlement and a potential right to recover expenses through litigation. The distinction is essential when researching Russian clinical genomics financing.

comments